Patents by Inventor Jonathan P. Hannan

Jonathan P. Hannan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Complement receptor 2 (CR2) targeting groups
    Patent number: 9650447
    Abstract: Provided herein are compositions and methods directed to soluble proteins which can selectively deliver modulators of complement activity. Targeted delivery of these modulators is accomplished by selectively mutating particular amino acids in a targeting protein portion of the composition corresponding to at least the first two N-terminal SCR domains of CR2. Depending on the particular combination of mutations introduced into the targeting portion, a complement activity modulator can be selectively delivered to particular ligands of CR2 at sites where complement system activation or suppression is desired.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: May 16, 2017
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: James M. Kovacs, Jonathan P. Hannan, V. Michael Holers
  • COMPLEMENT RECEPTOR 2 (CR2) TARGETING GROUPS
    Publication number: 20130190477
    Abstract: Provided herein are compositions and methods directed to soluble proteins which can selectively deliver modulators of complement activity. Targeted delivery of these modulators is accomplished by selectively mutating particular amino acids in a targeting protein portion of the composition corresponding to at least the first two N-terminal SCR domains of CR2. Depending on the particular combination of mutations introduced into the targeting portion, a complement activity modulator can be selectively delivered to particular ligands of CR2 at sites where complement system activation or suppression is desired.
    Type: Application
    Filed: May 13, 2011
    Publication date: July 25, 2013
    Applicant: The Regents of the University of Colorado
    Inventors: James M. Kovacs, Jonathan P. Hannan, V. Michael Holers
  • LIGAND-SPECIFIC NON-ANTIBODY COMPOUNDS THAT INHIBIT CR2 ACTIVATION AND METHODS OF USE THEREOF
    Publication number: 20120108492
    Abstract: The present invention describes a novel non-antibody ligand-specific compound that selectively binds to a complement receptor type 2 (CR2) protein, a ligand thereof, or both, wherein the compound competitively inhibits CR2 ligand's binding to a CR2 protein in a standard assay. The present invention also describes compositions and methods of use thereof.
    Type: Application
    Filed: September 18, 2009
    Publication date: May 3, 2012
    Applicant: The Regents of the University of Colorado
    Inventors: V. Michael Holers, Jonathan P. Hannan, James Kovacs